Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b RSVPreF3 OA vaccine in lung/renal transplant recipients vs healthy adults
jRCT2031230191Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Aug 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of GSK3003899A in respiratory syncytial virus disease (RSV) (3 arms), sponsored by GSK. Started Aug 2023; status: active, not recruiting.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2031230191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230191.